Anorexia-cachexia syndrome in cancer patients
The cancer anorexia-cachexia syndrome (CACS) is a common complication in advanced cancer patients. It is characterized by massive wasting of skeletal muscle and adipose tissue with involuntary weight loss, anemia, asthenia, and negative nitrogen balance due to immunological, physiological and metabo...
| Autor: | |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2006 |
| País: | Brasil |
| Institución: | Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
| Repositorio: | Revista Brasileira de Cancerologia (Online) |
| Idioma: | portugués |
| OAI Identifier: | oai:rbc.inca.gov.br:article/1910 |
| Acceso en línea: | https://rbc.inca.gov.br/index.php/revista/article/view/1910 |
| Access Level: | acceso abierto |
| Palabra clave: | Anorexia Caquexia Câncer Nutrição Cachexia Cancer Nutrition |
| Sumario: | The cancer anorexia-cachexia syndrome (CACS) is a common complication in advanced cancer patients. It is characterized by massive wasting of skeletal muscle and adipose tissue with involuntary weight loss, anemia, asthenia, and negative nitrogen balance due to immunological, physiological and metabolic changes. CACS is intensified by alterations in nutrient metabolism (carbohydrates, proteins, and lipids), hormonal changes (leptin, neuropeptide-Y, melanocortin, ghrelin), and increased serum cytokine levels (TNFa, IL-1, IL-6, IFN-g). Tumors produce factors that alter the patient's perception of food, particularly taste and smell, and cancer treatment contributes to CACS. Nutritional treatment uses special nutrients such as polyunsaturated fatty acids (EPA and DHA), the amino acids glutamine and arginine, and nucleotides. Nutritional and pharmacological treatment with appetite-stimulating drugs has yielded more positive results in patients with CACS. |
|---|